Avacta Group Plc (AVCTF)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -24.94 Million GBP | 36.34% |
| 2022 | -39.18 Million GBP | -48.92% |
| 2021 | -26.31 Million GBP | -39.3% |
| 2020 | -18.89 Million GBP | -95.09% |
| 2019 | -9.68 Million GBP | -9.67% |
| 2018 | -8.82 Million GBP | -38.67% |
| 2017 | -6.36 Million GBP | -37.01% |
| 2016 | -4.64 Million GBP | 53.49% |
| 2015 | -9.99 Million GBP | -569.64% |
| 2014 | -1.49 Million GBP | 1.91% |
| 2013 | -1.52 Million GBP | -37.52% |
| 2012 | -1.1 Million GBP | -87.14% |
| 2011 | -591 Thousand GBP | 68.55% |
| 2010 | -1.87 Million GBP | 30.02% |
| 2009 | -2.68 Million GBP | -82.85% |
| 2008 | -1.46 Million GBP | -20.46% |
| 2007 | -1.21 Million GBP | -1039.25% |
| 2006 | -107 Thousand GBP | 90.3% |
| 2005 | -1.1 Million GBP | -270.13% |
| 2004 | -298 Thousand GBP | -168.47% |
| 2003 | -111 Thousand GBP | 33.13% |
| 2002 | -166 Thousand GBP | -10.67% |
| 2001 | -150 Thousand GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -5.76 Million GBP | 81.13% |
| 2023 Q2 | -11.53 Million GBP | -100.0% |
| 2023 FY | -24.94 Million GBP | 36.34% |
| 2023 Q4 | -13.41 Million GBP | -100.0% |
| 2023 Q3 | -6.7 Million GBP | 41.84% |
| 2022 Q2 | -8.93 Million GBP | -98.87% |
| 2022 Q3 | -15.27 Million GBP | -70.88% |
| 2022 FY | -39.18 Million GBP | -48.92% |
| 2022 Q1 | -4.49 Million GBP | 72.11% |
| 2022 Q4 | -30.55 Million GBP | -100.05% |
| 2021 Q3 | -8.09 Million GBP | 20.59% |
| 2021 Q2 | -10.19 Million GBP | -100.33% |
| 2021 Q4 | -16.11 Million GBP | -99.07% |
| 2021 Q1 | -5.09 Million GBP | 57.22% |
| 2021 FY | -26.31 Million GBP | -39.3% |
| 2020 Q4 | -11.89 Million GBP | -100.0% |
| 2020 Q1 | -3.49 Million GBP | 0.0% |
| 2020 Q2 | -6.99 Million GBP | -100.0% |
| 2020 FY | -18.89 Million GBP | -95.09% |
| 2020 Q3 | -5.94 Million GBP | 14.95% |
| 2019 Q2 | -2.24 Million GBP | 0.0% |
| 2019 FY | -9.68 Million GBP | -9.67% |
| 2019 Q1 | -2.24 Million GBP | 56.88% |
| 2018 Q1 | -2.44 Million GBP | -23.58% |
| 2018 FY | -8.82 Million GBP | -38.67% |
| 2018 Q4 | -5.19 Million GBP | 0.0% |
| 2018 Q2 | -4.88 Million GBP | -100.0% |
| 2017 Q2 | -1.47 Million GBP | 0.0% |
| 2017 Q4 | -1.97 Million GBP | 0.0% |
| 2017 FY | -6.36 Million GBP | -37.01% |
| 2017 Q1 | -1.47 Million GBP | 14.21% |
| 2017 Q3 | -1.97 Million GBP | -34.32% |
| 2016 Q2 | -1.44 Million GBP | 0.0% |
| 2016 FY | -4.64 Million GBP | 53.49% |
| 2016 Q3 | -1.71 Million GBP | -18.46% |
| 2016 Q4 | -1.71 Million GBP | 0.0% |
| 2016 Q1 | -1.44 Million GBP | -64.94% |
| 2015 Q4 | -877 Thousand GBP | 0.0% |
| 2015 FY | -9.99 Million GBP | -569.64% |
| 2015 Q3 | -877 Thousand GBP | 47.01% |
| 2015 Q2 | -1.65 Million GBP | 0.0% |
| 2015 Q1 | -1.65 Million GBP | -109.1% |
| 2014 Q2 | -588.5 Thousand GBP | 0.0% |
| 2014 Q1 | -588.5 Thousand GBP | -301.71% |
| 2014 Q4 | -791.5 Thousand GBP | 0.0% |
| 2014 FY | -1.49 Million GBP | 1.91% |
| 2014 Q3 | -791.5 Thousand GBP | -34.49% |
| 2013 FY | -1.52 Million GBP | -37.52% |
| 2013 Q2 | -357 Thousand GBP | 0.0% |
| 2013 Q3 | -146.5 Thousand GBP | 58.96% |
| 2013 Q4 | -146.5 Thousand GBP | 0.0% |
| 2013 Q1 | -357 Thousand GBP | 11.52% |
| 2012 Q4 | -403.5 Thousand GBP | 0.0% |
| 2012 FY | -1.1 Million GBP | -87.14% |
| 2012 Q3 | -403.5 Thousand GBP | 0.0% |
| 2011 FY | -591 Thousand GBP | 68.55% |
| 2010 FY | -1.87 Million GBP | 30.02% |
| 2009 FY | -2.68 Million GBP | -82.85% |
| 2008 FY | -1.46 Million GBP | -20.46% |
| 2007 FY | -1.21 Million GBP | -1039.25% |
| 2006 FY | -107 Thousand GBP | 90.3% |
| 2005 FY | -1.1 Million GBP | -270.13% |
| 2004 FY | -298 Thousand GBP | -168.47% |
| 2003 FY | -111 Thousand GBP | 33.13% |
| 2002 FY | -166 Thousand GBP | -10.67% |
| 2001 FY | -150 Thousand GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 66.721% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -279.358% |
| SQZ Biotechnologies Company | -79.46 Million USD | 68.606% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 147.088% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 138.302% |
| Mesoblast Limited | -87.95 Million USD | 71.637% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1270.317% |
| Genus plc | 7.9 Million USD | 415.785% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -129.045% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -572.383% |
| Marizyme, Inc. | -65.34 Million USD | 61.824% |
| ContraFect Corporation | -65.15 Million USD | 61.71% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -182.078% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -410.575% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -1344.148% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -762.504% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -209.528% |
| MultiCell Technologies, Inc. | -380.07 USD | -6563690.881% |
| Accustem Sciences Inc. | -3.74 Million USD | -565.889% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 51.739% |
| EV Biologics, Inc. | -1.26 Million USD | -1868.774% |
| Q BioMed Inc. | -2.05 Million USD | -1115.686% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -568.283% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3844.77% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -947.81% |
| Biomind Labs Inc. | -1.21 Million USD | -1954.403% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -136.509% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -215.661% |
| Skye Bioscience, Inc. | -37.64 Million USD | 33.731% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -1049.73% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -166479.861% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -257.262% |
| IMV Inc. | -36.48 Million USD | 31.625% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -57.182% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -328.845% |
| GB Sciences, Inc. | -1.36 Million USD | -1732.079% |
| Alpha Cognition Inc. | -13.77 Million USD | -81.135% |
| HST Global, Inc. | -146.21 Thousand USD | -16962.444% |
| CSL Limited | 2.64 Billion USD | 100.944% |
| Halberd Corporation | -79.67 Thousand USD | -31210.558% |
| Enzolytics Inc. | -2.17 Million USD | -1046.023% |
| Resverlogix Corp. | -3.61 Million USD | -591.053% |
| Affymax, Inc. | -14.42 Million USD | -72.955% |
| SYBLEU INC | -180.3 Thousand USD | -13736.077% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -686.615% |
| argenx SE | -295.05 Million USD | 91.545% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 60.148% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 25556.122% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -527.915% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -724.385% |
| AVAX Technologies, Inc. | -6.41 Million USD | -288.967% |
| Zenith Capital Corp. | -10.59 Million USD | -135.438% |
| Genscript Biotech Corporation | -95.47 Million USD | 73.871% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -107235.857% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -501.722% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -41175.229% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 58.23% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -704.283% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -2262.278% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -1179.826% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -553.234% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1144.168% |
| BioStem Technologies, Inc. | -8.48 Million USD | -194.083% |
| ONE Bio Corp. | 8.67 Million USD | 387.52% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -5552.187% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1768.086% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -1321.667% |
| Agentix Corp. | -1.37 Million USD | -1715.369% |
| LadRx Corporation | 400.44 Thousand USD | 6329.85% |
| Cell Source, Inc. | -5.32 Million USD | -368.822% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -5904.395% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2537.402% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2537.402% |
| NovAccess Global Inc. | -4.76 Million USD | -423.087% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 460.267% |
| Itoco Inc. | -1.86 Million USD | -1234.782% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -461.549% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -1394.727% |
| Kadimastem Ltd | -3.3 Million USD | -654.279% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -9024.659% |
| CytoDyn Inc. | -49.84 Million USD | 49.947% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -31465.296% |
| Mobile Lads Corp. | -2.26 Million USD | -1002.244% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -10835.575% |
| Qrons Inc. | -789.34 Thousand USD | -3060.46% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -2549.626% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -1094.962% |
| Rebus Holdings, Inc. | -1.02 Million USD | -2345.784% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -1446.873% |
| International Stem Cell Corporation | -131 Thousand USD | -18943.511% |
| Bioxytran, Inc. | -4.28 Million USD | -482.874% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -45866.613% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -885.951% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 48.105% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -1080.085% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -3094.7% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -687.468% |
| Neutra Corp. | -233.46 Thousand USD | -10585.542% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -22.946% |
| PureTech Health plc | -65.69 Million USD | 62.027% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -17.306% |
| IXICO plc | -1.17 Million USD | -2017.742% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -151.305% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 56.331% |
| CSL Limited | 2.64 Billion USD | 100.944% |
| Cellectis S.A. | -103.17 Million USD | 75.82% |